<DOC>
	<DOCNO>NCT02961790</DOCNO>
	<brief_summary>This randomized phase III trial study well oxybutynin chloride work manage hot flash patient candidate , interested hormone replacement therapy . Previous study show oxybutynin effective manage hot flash , however dos use prior study result side effect . This trial evaluate low dos oxybutynin goal determine efficacious less side effect .</brief_summary>
	<brief_title>Oxybutynin Chloride Managing Hot Flashes</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether oxybutynin chloride ( oxybutynin ) diminish hot-flash activity woman history breast cancer woman concern take estrogen fear breast cancer . SECONDARY OBJECTIVES : I . To perform dose-response evaluation two oxybutynin dos . II . To determine toxicity oxybutynin study population . III . To assess impact hot-flash activity overall quality life examine whether oxybutynin diminish impact quality life . OUTLINE : Patients randomize 1 4 group . GROUP I ( LOW-DOSE OXUBUTYNIN CHLORIDE ) : Patients receive low dose oxybutynin chloride orally ( PO ) twice day ( BID ) day 8-49 absence unacceptable toxicity . GROUP II ( LOW-DOSE PLACEBO ) : Patients receive low dose placebo PO BID day 8-49 absence unacceptable toxicity . GROUP III ( HIGH-DOSE OXUBUTYNIN CHLORIDE ) : Patients receive low dose oxybutynin chloride PO BID day 8-14 high dose oxybutynin chloride day 15-49 absence unacceptable toxicity . GROUP IV ( HIGH-DOSE PLACEBO ) : Patients receive low dose placebo PO BID day 8-14 high dose placebo day 15-49 absence unacceptable toxicity .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal , Breast</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Carcinoma , Lobular</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Mandelic Acids</mesh_term>
	<criteria>History breast cancer , ductal breast carcinoma situ ( DCIS ) , lobular carcinoma situ ( LCIS ) ( currently without evidence malignant disease ) OR concern take estrogen fear breast cancer Bothersome hot flash ( define occurrence &gt; = 28 time per week sufficient severity prompt patient seek therapeutic intervention ) Presence hot flash &gt; 30 day prior study entry Ability complete questionnaire ( ) assistance Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) = 0 , 1 Ability provide inform write consent Life expectancy &gt; = 6 month Willing work enrol institution followup ( active monitoring phase study ) Any follow current ( = &lt; 4 week prior ) plan therapy : Antineoplastic chemotherapy ( antiHER2 agent allow ) Androgens Estrogens ( delivery route ) Progestogens Tamoxifen , raloxifene aromatase inhibitor allow , patient must constant dose least 28 day must expect stop medication study period Selective serotonin reuptake inhibitor ( SSRIs ) / serotoninnorepinephrine reuptake inhibitor ( SNRIs ) Gabapentin Clonidine Agents known anticholinergic activity Prior use oxybutynin period patient hot flash Pregnant woman Nursing woman History follow contraindication oxybutynin : Gastroparesis gastrointestinal obstructive disorder Significant gastric reflux symptom Ulcerative colitis Narrowangle glaucoma Urinary retention Hypersensitivity oxybutynin component product Current uncontrolled hyperthyroidism Coronary heart disease ( angina prior myocardial infarction ) Congestive heart failure Symptomatic cardiac arrhythmia Current uncontrolled hypertension Myasthenia gravis Dementia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>